-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 12, 2022, Australian biotech company CSL said it could not close the deal by June 2022 as previously expected, as regulators need additional months to review its acquisition of Vifor Phar.
It is worth noting that CSL’s $17 billion acquisition of Swiss pharmaceutical company Vifor Pharma is the largest M&A transaction in the biopharmaceutical industry in 202 The deal, announced on December 14, 2021, represents a premium of 40% to the 60-day average price of Vifor sto.
For CSL, the successful acquisition of Vifor is of great significan.
The acquisition of Vifor can increase the diversification of CSL's products, and Vifor's drugs for kidney disease and iron deficiency can enable CSL to enter the field of specialty dru.
Winning the green light for antitrust scrutiny is the last hurdle in CSL's acquisition of Vif.
Both companies said delays in the regulatory approval process are not uncommon, and that both parties will continue to work with antitrust regulators and remain confident in completing the acquisiti.
Original in English: https://
Original in English: https://
Original in English: https://
Original in English: https:// href="https://" target="_blank"> https:// csls-117b-vifor-buy-largest-biopharma-ma-deal-2021-hits-antitrust-delay
